Centre of Evidence Based Dermatology
  • Print

CEBD Coronavirus Dermatology Resource

 

Journal articles - Hydroxychloroquine, chloroquine, antibiotics & other coronavirus treatments

[Selected articles of dermatological relevance]

 

Review of adverse cutaneous reactions of pharmacologic interventions for coronavirus disease 2019 (COVID-19): a guide for the dermatologist.
Martinez-Lopez A, Cuenca-Barrales C, Montero-Vilchez T, Molina-Leyva A, Arias-Santiago S.
J Am Acad Dermatol. 2020 Aug 7:S0190-9622(20)32358-6. doi: 10.1016/j.jaad.2020.08.006. Online ahead of print. Review.
https://doi.org/10.1016/j.jaad.2020.08.006

Androgen sensitivity in COVID-19 and antiandrogens: prospective data are still needed.
Ianhez M, Ramos PM, Goren A, Miot HA.
Dermatol Ther. 2020 Aug 9:e14166. doi: 10.1111/dth.14166. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1111/dth.14166

COVID-19 and immunological regulations - from basic and translational aspects to clinical implications.
Schön MP, Berking C, Biedermann T, Buhl T, Erpenbeck L, Eyerich K, Eyerich S, Ghoreschi K, Goebeler M, Ludwig RJ, Schäkel K, Schilling B, Schlapbach C, Stary G, von Stebut E, Steinbrink K.
J Dtsch Dermatol Ges. 2020 Aug 6. doi: 10.1111/ddg.14169. Online ahead of print. Review.
https://doi.org/10.1111/ddg.14169

Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus.
Leung AK, McMillan T, Human A, Lam JM.
Drugs Context. 2020 Jul 20;9:2020-5-8. doi: 10.7573/dic.2020-5-8. eCollection 2020. Case report.
https://doi.org/10.7573/dic.2020-5-8

Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19.
Herman A, Matthews M, Mairlot M, Nobile L, Fameree L, Jacquet LM, Baeck M.
J Eur Acad Dermatol Venereol. 2020 Jul 31. doi: 10.1111/jdv.16838. Online ahead of print. Case report.
https://doi.org/10.1111/jdv.16838

Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
Manjaly Thomas ZR, Leuppi-Taegtmeyer A, Jamiolkowski D, Steveling-Klein E, Bellutti-Enders F, Hofmeier KS, Hartmann K.
J Allergy Clin Immunol. 2020 Jul 22:S0091-6749(20)31025-3. doi: 10.1016/j.jaci.2020.07.008. Online ahead of print. Review.
https://doi.org/10.1016/j.jaci.2020.07.008

Hydroxychloroquine in dermatology and beyond: Recent update.
Sardana K, Sinha S, Sachdeva S.
Indian Dermatol Online J. 2020 May 10;11(3):453-464. doi: 10.4103/idoj.IDOJ_280_20. eCollection 2020 May-Jun. Review.
http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7367590/

Hydroxychloroquine, dermatology and SARS-CoV-2: Updating an old association.
Diotallevi F, Campanati A, Radi G, Luchetti MM, Benfaremo D, Tagliati C, Simonetti O, Offidani A.
J Med Virol. 2020 Jul 21. doi: 10.1002/jmv.26322. Online ahead of print. Report / commentary.
https://doi.org/10.1002/jmv.26322

First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test.
Jimenez AC, Navarrate Navarrete N, Gratacós Gómez AR, Florido López F, Garcia Rodriguez R, Elisa GT.
Contact Dermatitis. 2020 Jul 12. doi: 10.1111/cod.13657. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/cod.13657

Retrospective analysis of dermatological adverse events associated with hydroxychloroquine reported to the United States Food and Drug Administration.
Lipner SR, Wang Y.
J Am Acad Dermatol. 2020 Jul 8. pii: S0190-9622(20)32171-X. doi: 10.1016/j.jaad.2020.07.007. [Epub ahead of print] No abstract available. Research study.
https://doi.org/10.1016/j.jaad.2020.07.007

How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology.
Jessica Chang TY, Pope JE.
Immunotherapy. 2020 Jul 9. doi: 10.2217/imt-2020-0153. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.2217/imt-2020-0153

Angiotensin II receptors - Impact for COVID-19 severity.
Aksoy H, Karadag AS, Wollina U.
Dermatol Ther. 2020 Jul 9:e13989. doi: 10.1111/dth.13989. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13989

Potential role of IL-17 blocking agents in the treatment of severe COVID-19?
Bulat V, Situm M, Azdajic MD, Likic R.
Br J Clin Pharmacol. 2020 Jul 5. doi: 10.1111/bcp.14437. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1111/bcp.14437

Hydroxychloroquine-induced Stevens-Johnson syndrome in COVID-19: a rare case report.
Davoodi L, Jafarpour H, Kazeminejad A, Soleymani E, Akbari Z, Razavi A.
Oxf Med Case Reports. 2020 Jun 25;2020(6):omaa042. doi: 10.1093/omcr/omaa042. eCollection 2020 Jun. Case report.
https://doi.org/10.1093/omcr/omaa042

Potential use of turmeric in COVID-19.
Gupta H, Gupta M, Bhargava S.
Clin Exp Dermatol. 2020 Jul 1. doi: 10.1111/ced.14357. [Epub ahead of print]. Commentary.
https://doi.org/10.1111/ced.14357

Colchicin treatment of Covid-19 presenting with cutaneous rash and myopericarditis.
Recalcati S, Piconi S, Franzetti M, Barbagallo T, Prestinari F, Fantini F.
Dermatol Ther. 2020 Jun 25. doi: 10.1111/dth.13891. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13891

Considerations of managing lichen planopilaris with hydroxychloroquine during the COVID-19 pandemic.
Dadkhahfar S, Araghi F, Tabary M, Moravvej H.
J Drugs Dermatol. 2020 Jun 1;19(6):679-680. No abstract available. Review / commentary.
https://jddonline.com/articles/dermatology/S1545961620P0679X

Biologics and small molecules in the treatment of COVID-19.
Murrell DF, Rudnicka L, Shivakumar S, Kassir M, Jafferany M, Galadari H, Lotti T, Sadoughifar R, Sitkowska Z, Goldust M.
J Drugs Dermatol. 2020 Jun 1;19(6):673-675. No abstract available. Review / commentary.
https://jddonline.com/articles/dermatology/S1545961620P0673X

Cutaneous side effects of hydroxychloroquine in health care workers in a COVID referral hospital - implications for clinical practice.
Sardana K, Mathachan SR, Deepak D, Khurana A, Sinha S.
J Dermatolog Treat. 2020 Jun 22:1-3. doi: 10.1080/09546634.2020.1781041. [Epub ahead of print]. Case reports.
https://doi.org/10.1080/09546634.2020.1781041

Utility and risk of dermatologic medications during the COVID-19 pandemic.
Goldust M, Hartmann K, Abdelmaksoud A, Navarini AA.
Dermatol Ther. 2020 Jun 15. doi: 10.1111/dth.13833. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13833

Treatment of Covid19 - Repurposing drugs commonly used in dermatology.
Stojkovic-Filipovic J, Bosic M.
Dermatol Ther. 2020 Jun 15. doi: 10.1111/dth.13829. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13829

Comment on "Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine": report of a COVID-19 patient with particular findings.
Suarez-Valle A, Fernandez-Nieto D, Melian-Olivera A, Dominguez-Santas M, Diaz-Guimaraens B, Del Real CMG, Jimenez-Cauhe J.
Dermatol Ther. 2020 Jun 16:e13852. doi: 10.1111/dth.13852. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13852

Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19.
Enos T, Jeong HS, Vandergriff T, Jacobe HT, Chong BF.
Dermatol Ther. 2020 Jun 15. doi: 10.1111/dth.13834. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13834

Further aspects of doxycycline therapy in COVID-19.
Szolnoky G.
Dermatol Ther. 2020 Jun 13:e13810. doi: 10.1111/dth.13810. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13810

Dermatological therapies with relevance to COVID-19.
Shishak M, Sarkar R.
Dermatol Ther. 2020 Jun 11:e13813. doi: 10.1111/dth.13813. [Epub ahead of print]. Review / commentary.
https://doi.org/10.1111/dth.13813

Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19.
Delaleu J, Deniau B, Battistella M, de Masson A, Bensaid B, Jachiet M, Lazaridou I, Bagot M, Bouaziz JD; Saint-Louis CORE (COvid REsearch) group.
J Allergy Clin Immunol Pract. 2020 Jun 7. pii: S2213-2198(20)30587-0. doi: 10.1016/j.jaip.2020.05.046. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1016/j.jaip.2020.05.046

Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19.
Monte Serrano J, Cruañes Monferrer J, García-García M, García-Gil MF.
Med Clin (Barc). 2020 May 19. pii: S0025-7753(20)30280-3. doi: 10.1016/j.medcli.2020.05.004. [Epub ahead of print] English, Spanish. No abstract available. Case report.
https://doi.org/10.1016/j.medcli.2020.05.004

Omalizumab and COVID19 treatment: Could it help?
Abdelmaksoud A, Goldust M, Vestita M.
Dermatol Ther. 2020 Jun 8:e13792. doi: 10.1111/dth.13792. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1111/dth.13792

Azithromycin and COVID-19. Prompt early use at first signs of this infection in adults and children: an approach worthy of consideration.
Schwartz RA, Suskind RM.
Dermatol Ther. 2020 Jun 8:e13785. doi: 10.1111/dth.13785. [Epub ahead of print]. Commentary.
https://doi.org/10.1111/dth.13785

Back to the basics: Propolis and COVID-19.
Bachevski D, Damevska K, Simeonovski V, Dimova M.
Dermatol Ther. 2020 Jun 7:e13780. doi: 10.1111/dth.13780. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1111/dth.13780

Advances in skin science enable the development of a COVID-19 vaccine.
Falo LD Jr.
J Am Acad Dermatol. 2020 May 30. pii: S0190-9622(20)31002-1. doi: 10.1016/j.jaad.2020.05.126. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1016/j.jaad.2020.05.126

Potential role of Anti-IL-17 in COVID-19 treatment.
Ayhan E, Öztürk M, An İ, Abdelmaksoud A, Araç E.
Dermatol Ther. 2020 May 30:e13715. doi: 10.1111/dth.13715. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13715

Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?
Seirafianpour F, Mozafarpoor S, Fattahi N, Sadeghzadeh-Bazargan A, Hanifiha M, Goodarzi A.
Dermatol Ther. 2020 May 30. doi: 10.1111/dth.13733. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13733

Prescription restrictions on hydroxychloroquine among the largest Florida pharmacy chains during the COVID-19 pandemic: An observational study.
Hadeler E, Bray F.
J Am Acad Dermatol. 2020 May 22. pii: S0190-9622(20)30964-6. doi: 10.1016/j.jaad.2020.05.092. [Epub ahead of print] No abstract available. Observational study.
https://doi.org/10.1016/j.jaad.2020.05.092

Hydroxychloroquine effects on psoriasis: a systematic review and a cautionary note for COVID-19 treatment.
Sachdeva M, Mufti A, Maliyar K, Lytvyn Y, Yeung J.
J Am Acad Dermatol. 2020 May 19. pii: S0190-9622(20)30942-7. doi: 10.1016/j.jaad.2020.05.074. [Epub ahead of print]. Systematic review.
https://doi.org/10.1016/j.jaad.2020.05.074

Dermatologic manifestations of hydroxychloroquine therapy: a closer look at the nails.
Lipner SR, Scher RK.
J Am Acad Dermatol. 2020 May 18. pii: S0190-9622(20)30929-4. doi: 10.1016/j.jaad.2020.04.177. [Epub ahead of print] No abstract available. Commentary / review.
https://doi.org/10.1016/j.jaad.2020.04.177

Hydroxychloroquine shortages during the COVID-19 pandemic.
Mendel A, Bernatsky S, Thorne JC, Lacaille D, Johnson SR, Vinet É.
Ann Rheum Dis. 2020 May 20. pii: annrheumdis-2020-217835. doi: 10.1136/annrheumdis-2020-217835. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1136/annrheumdis-2020-217835

The COVID-19 chemoprophylactic conundrum - Are we limiting available resources?
Sharma A, Mhatre M, Goldust M, Jindal V, Singla P.
Dermatol Ther. 2020 May 17:e13607. doi: 10.1111/dth.13607. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1111/dth.13607

Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine.
Litaiem N, Hajlaoui K, Karray M, Slouma M, Zeglaoui F.
Dermatol Ther. 2020 May 13:e13565. doi: 10.1111/dth.13565. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13565

Systemic immunobiological, immunosuppressant and oncologic agents for the treatment of dermatologic diseases during the SARS-Cov-2 (COVID19) pandemic emergency: A quick review for a quick consultation.
Paolino G, Mercuri SR, Bearzi P, Mattozzi C.
Dermatol Ther. 2020 May 8:e13537. doi: 10.1111/dth.13537. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13537

Acute generalized exanthematous pustulosis with erythema multiforme-like lesions in a COVID-19 woman.
Robustelli Test E, Vezzoli P, Carugno A, Raponi F, Gianatti A, Rongioletti F, Sena P.
J Eur Acad Dermatol Venereol. 2020 May 9. doi: 10.1111/jdv.16613. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16613

The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic.
Shah M, Sachdeva M, Dodiuk-Gad RP.
Dermatol Ther. 2020 May 7. doi: 10.1111/dth.13524. [Epub ahead of print] No abstract available. Letter / commentary.
https://doi.org/10.1111/dth.13524

Can hydroxychloroquine be useful in the prevention of COVID-19? An Italian survey in dermatological and rheumatological patients already under treatment.
Vastarella M, Patrì A, Annunziata MC, Cantelli M, Nappa P, Tasso M, Costa L, Caso F, Fabbrocini G.
J Am Acad Dermatol. 2020 Apr 30. pii: S0190-9622(20)30757-X. doi: 10.1016/j.jaad.2020.04.136. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1016/j.jaad.2020.04.136

Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight.
Grandolfo M, Romita P, Bonamonte D, Cazzato G, Hansel K, Stingeni L, Conforti C, Giuffrida R, Foti C.
Dermatol Ther. 2020 May 2. doi: 10.1111/dth.13499. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13499

Cutaneous side-effects of the potential Covid-19 drugs.
Türsen Ü, Türsen B, Lotti T.
Dermatol Ther. 2020 May 1:e13476. doi: 10.1111/dth.13476. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13476

Risks of hydroxychloroquine use for COVID-19 prophylaxis.
Sachdeva M, Shah M, Ziv M, Leshem E, Dodiuk-Gad RP.
J Am Acad Dermatol. 2020 Apr 26. pii: S0190-9622(20)30727-1. doi: 10.1016/j.jaad.2020.04.111. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.04.111

Response to "Risks of Hydroxychloroquine use for COVID-19 prophylaxis".
Grant-Kels JM.
J Am Acad Dermatol. 2020 Apr 26. pii: S0190-9622(20)30728-3. doi: 10.1016/j.jaad.2020.04.112. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.04.112

Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.
Mathian A, Mahevas M, et al.
Ann Rheum Dis. 2020 Apr 24. pii: annrheumdis-2020-217566. doi: 10.1136/annrheumdis-2020-217566. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1136/annrheumdis-2020-217566

Applying the ethical principles of resource allocation to drugs in limited supply during a public health crisis.
Kong HE, Grant-Kels JM, Stoff BK.
J Am Acad Dermatol. 2020 Apr 21. pii: S0190-9622(20)30693-9. doi: 10.1016/j.jaad.2020.04.078. [Epub ahead of print] No abstract available. Commentary / review.
https://doi.org/10.1016/j.jaad.2020.04.078

Dermatoethics: Self-prescribing Plaquenil during the COVID-19 pandemic.
Stoj VJ, Grant-Kels JM.
Int J Womens Dermatol. 2020 Apr 23. doi: 10.1016/j.ijwd.2020.04.006. [Epub ahead of print] No abstract available. Commentary / review.
https://doi.org/10.1016/j.ijwd.2020.04.006

A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19).
Shah S, Das S, Jain A, Misra DP, Negi VS.
Int J Rheum Dis. 2020 Apr 13. doi: 10.1111/1756-185X.13842. [Epub ahead of print]. Systematic review.
https://doi.org/10.1111/1756-185X.13842

Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?
Moiseev S, Avdeev S, Brovko M, Novikov P, Fomin V.
Ann Rheum Dis. 2020 Apr 21. pii: annrheumdis-2020-217570. doi: 10.1136/annrheumdis-2020-217570. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1136/annrheumdis-2020-217570

Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL-6 in COVID-19 outbreak.
Conforti C, Giuffrida R, Zalaudek I, Di Meo N.
Dermatol Ther. 2020 Apr 20:e13437. doi: 10.1111/dth.13437. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/dth.13437

Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review.
Sharma AN, Mesinkovska NA, Paravar T.
J Am Acad Dermatol. 2020 Apr 11. pii: S0190-9622(20)30564-8. doi: 10.1016/j.jaad.2020.04.024. [Epub ahead of print]. Systematic review.
https://doi.org/10.1016/j.jaad.2020.04.024

Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19.
Picot S, Marty A, Bienvenu AL, Blumberg LH, Dupouy-Camet J, Carnevale P, Kano S, Jones MK, Daniel-Ribeiro CT, Mas-Coma S.
One Health. 2020 Apr 4:100131. doi: 10.1016/j.onehlt.2020.100131. [Epub ahead of print]. Editorial.
https://doi.org/10.1016/j.onehlt.2020.100131

Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?
Patrì A, Fabbrocini G.
J Am Acad Dermatol. 2020 Apr 10. pii: S0190-9622(20)30557-0. doi: 10.1016/j.jaad.2020.04.017. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.04.017

Does hydroxychloroquine combat COVID-19? A timeline of evidence.
Alia E, Grant-Kels JM.
J Am Acad Dermatol. 2020 Apr 10. pii: S0190-9622(20)30607-1. doi: 10.1016/j.jaad.2020.04.031. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1016/j.jaad.2020.04.031

Generalized pustular figurate erythema a newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.
Schwartz RA, Janniger CK.
Dermatol Ther. 2020 Apr 6. doi: 10.1111/dth.13380. [Epub ahead of print]. Review / commentary.
https://www.ncbi.nlm.nih.gov/pubmed/32253799

A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?
Kutlu Ö, Metin A.
Dermatol Ther. 2020 Apr 7:e13383. doi: 10.1111/dth.13383. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13383

Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: What every clinician should know.
Yazdany J, Kim AHJ.
Ann Intern Med. 2020 Mar 31. doi: 10.7326/M20-1334. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.7326/M20-1334

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China.
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X, Zhang S.
Clin Immunol. 2020 Mar 25:108393. doi: 10.1016/j.clim.2020.108393. [Epub ahead of print] Review.
https://doi.org/10.1016/j.clim.2020.108393 

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D.
Int J Antimicrob Agents. 2020 Mar 20:105949. doi: 10.1016/j.ijantimicag.2020.105949. [Epub ahead of print]. Clinical trial.
https://www.ncbi.nlm.nih.gov/pubmed/32205204

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.
Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S.
J Crit Care. 2020 Mar 10. pii: S0883-9441(20)30390-7. doi: 10.1016/j.jcrc.2020.03.005. [Epub ahead of print]. Systematic review.
https://www.ncbi.nlm.nih.gov/pubmed/32173110 

 

Back to CEBD Coronavirus Dermatology Resource Homepage

Centre of Evidence Based Dermatology

The University of Nottingham
King's Meadow Campus
Lenton Lane
Nottingham, NG7 2NR


telephone: +44 (0) 115 823 1048
email:cebd@nottingham.ac.uk